Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Efecto sostenido del seralutinib sobre biomarcadores circulantes en el estudio de extensión de etiqueta abierta de la fase 2 TORREY

Thursday, July 10, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the sustained effects of seralutinib on circulating biomarkers in the open-label extension study of Phase 2 TORREY. This study highlights the potential benefits of seralutinib for patients suffering from pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The findings suggest a promising avenue for further research and development.
Price reaction · baseline $1.36 (2025-07-09 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib shows sustained effects on circulating biomarkers.
  • The study is part of an open-label extension of Phase 2 TORREY.
  • Positive implications for patients with PAH and PH-ILD.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Efecto sostenido del seralutinib sobre biomarcadores circulantes en el estudio de extensión de etiqueta abierta de la fase 2 TORREY
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is seralutinib?

Seralutinib is a medication being studied for its effects on pulmonary arterial hypertension and related conditions.

What does the TORREY study focus on?

The TORREY study focuses on the effects of seralutinib on circulating biomarkers in patients.

What conditions does seralutinib target?

Seralutinib targets pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

What phase is the TORREY study in?

The TORREY study is in Phase 2 and includes an open-label extension.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib phase 2 TORREY study PAH PH-ILD
Last updated: Jul 10, 2025

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →